News
BBI
--
0.00%
--
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 2d ago
Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021
BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating sk...
GlobeNewswire · 6d ago
Brickell Biotech completes patient enrollment in late-stage sweat disorder study
Brickell Biotech (BBI) announces the completion of patient enrollment in the Phase 3 pivotal Cardigan I study evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis.Shares up more
Seekingalpha · 04/27 11:46
BRIEF-Brickell Biotech Completes Patient Enrollment In U.S. Phase 3 Pivotal Cardigan I Study Of Sofpironium Bromide Gel, 15% For The Treatment Of Primary Axillary Hyperhidrosis
reuters.com · 04/27 11:36
Analysts Are Bullish on Top Healthcare Stocks: Brickell Biotech (BBI), Infusystems Holdings (INFU)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Brickell Biotech (BBI) and Infusystems Holdings (INFU) with
SmarterAnalyst · 04/26 10:55
DJ Brickell Biotech Shares Rise 10% After Positive Results in Safety Study
Dow Jones · 04/23 17:34
BRIEF-Brickell Biotech Reports Results From U.S. Phase 3 Open-Label, Long-Term Safety Study On Chronic Use Of Sofpironium Bromide Gel As A Potential Treatment For Primary Axillary Hyperhidrosis
reuters.com · 04/23 15:55
Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel As Treatment For Primary Axillary Hyperhidrosis
Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the
Benzinga · 04/23 14:04
BRIEF-Brickell Biotech Announces Publication Of HDSM-AX Patient Reported Outcome Scale Validation Results In The Journal Of Drugs In Dermatology
reuters.com · 04/15 12:36
Brickell Biotech Highlights Publication Of Its HDSM-Ax Patient Reported Outcome Scale Validation Results In Journal Of Drugs In Dermatology
Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the
Benzinga · 04/15 12:15
Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology
Brickell Biotech, Inc. (“Brickell” or the “Company”) (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the
Benzinga · 04/15 12:12
Brickell Biotech (BBI) Receives a Buy from Oppenheimer
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Brickell Biotech (BBI), with a price target of $5.00. The
SmarterAnalyst · 03/29 12:32
Neos Therapeutics, Aytu BioScience leads healthcare gainers; Translate Bio, ContraFect among major losers
Gainers: Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU) +14%, Vericel (VCEL) +14%, Brickell Biotech (BBI) +14%, Infinity Pharmaceuticals INFI +13%.Losers: Translate Bio TBIO -32%, ContraFect CFRX -13%, Lipocine (LPCN) -11%, Olema Pharmaceuticals (OLM...
Seekingalpha · 03/18 15:02
HEXO, CSIQ, LAZR and SIG among premarket gainers
BioHiTech Global (BHTG) +44% on receiving $2M in Digester orders.Upstart Holdings (UPST) +39% on Q4 results.Neos Therapeutics (NEOS) +30%.Seneca Biopharma (SNCA) +26%.Evolving Systems (EVOL) +24% on Q4 results.Can-Fite BioPharma (CANF) +17% on announcing n...
Seekingalpha · 03/18 12:29
BRIEF-Brickell Biotech Files For Common Stock Offering Of Up To $50 Mln
reuters.com · 03/17 20:46
Tupperware Brands, Oragenics leads the premarket losers' pack
Sundance Energy (SNDE) -42% on filing for voluntary Chapter 11 protection to strengthen balance sheet and position business for sustained future success, commences financial restructuring with lender support.INVO Bioscience (INVO) -17%.Tupperware
Seekingalpha · 03/10 13:34
The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 9)
Benzinga · 03/10 12:25
DJ Brickell Biotech, Inc. CEO Robert Brown on Q4 2020 Results -- Earnings Call Transcript >BBI
Dow Jones · 03/10 03:51
BRIEF-Brickell Biotech Reports Fourth Quarter And Full Year 2020 Financial Results
reuters.com · 03/09 22:42
Webull provides a variety of real-time BBI stock news. You can receive the latest news about Brickell Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About BBI
Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.